Bibliographic Details
| Title: |
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. |
| Authors: |
Liu, J. F.1 joyce_liu@dfci.harvard.edu, Moore, K. N.2, Birrer, M. J.3, Berlin, S.1,4, Matulonis, U. A.1, Infante, J. R.5, Wolpin, B.1, Poon, K. A.6, Firestein, R.6, Xu, J.6, Kahn, R.6, Wang, Y.6, Wood, K.6, Darbonne, W. C.6, Lackner, M. R.6, Kelley, S. K.6, Lu, X.6, Choi, Y. J.6, Maslyar, D.6, Humke, E. W.6 |
| Source: |
Annals of Oncology. Nov2016, Vol. 27 Issue 11, p2124-2130. 7p. 3 Graphs. |
| Database: |
Academic Search Ultimate |
